Mixed Results for Drug in Eosinophilic Gastritis

Mixed Results for Drug in Eosinophilic Gastritis

TOPLINE: Benralizumab, an eosinophil-depleting monoclonal antibody, induces histologic remission in patients with eosinophilic gastritis, but persistence of other disease features suggest coexisting eosinophil-independent pathogenic mechanisms. METHODOLOGY: Investigators conducted a single-site, double-blind, placebo-controlled phase 2 trial. The trial include 26 patients…

Read More